{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:26:25Z","timestamp":1772814385125,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["ZHYX202219"],"award-info":[{"award-number":["ZHYX202219"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.177989","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T08:06:35Z","timestamp":1754467595000},"page":"177989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Concomitant use of low molecular weight heparin mitigates bortezomib-induced peripheral Neuropathy: Analysis of the FDA adverse event reporting system"],"prefix":"10.1016","volume":"1005","author":[{"given":"Yibei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongzhi","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejphar.2025.177989_bib1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke Statistics-2018 update: a report from the American heart association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177989_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil--free eyeballs on AERS pharmacovigilance data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177989_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ejphar.2025.177989_bib4","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ejphar.2025.177989_bib5","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/S0959-8049(02)00229-0","article-title":"Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity","volume":"38","author":"Cavaletti","year":"2002","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.ejphar.2025.177989_bib6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Cengiz Seval","year":"2018","journal-title":"Expet Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177989_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"51","key":"10.1016\/j.ejphar.2025.177989_bib8","doi-asserted-by":"crossref","first-page":"39888","DOI":"10.1074\/jbc.M110.128348","article-title":"High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity","volume":"285","author":"Evankovich","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177989_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2018.03.022","article-title":"Mechanism of cardiovascular toxicity by proteasome inhibitors: new paradigm derived from clinical and pre-clinical evidence","volume":"828","author":"Gavazzoni","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177989_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and arterial thromboembolism in patients with cancer: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC CardioOncology"},{"issue":"10","key":"10.1016\/j.ejphar.2025.177989_bib11","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2174\/1386207325666220524144147","article-title":"Mechanistic involvement of inflammation in bortezomib-induced peripheral neuropathy","volume":"25","author":"Goel","year":"2022","journal-title":"Comb. Chem. High Throughput Screen."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177989_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12916-022-02713-6","article-title":"Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation","volume":"21","author":"Guo","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.ejphar.2025.177989_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","article-title":"Low molecular weight heparins and their clinical applications","volume":"163","author":"Hao","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177989_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40360-020-00447-w","article-title":"Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system","volume":"21","author":"Huang","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177989_bib15","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41598-020-61571-5","article-title":"Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system","volume":"10","author":"Huang","year":"2020","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/j.ejphar.2025.177989_bib16","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1001\/jama.1993.03500210065033","article-title":"Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems","volume":"269","author":"Kessler","year":"1993","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ejphar.2025.177989_bib17","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177989_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11239-020-02354-7","article-title":"Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?","volume":"52","author":"Lapietra","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"issue":"7","key":"10.1016\/j.ejphar.2025.177989_bib19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177989_bib20","first-page":"203","article-title":"Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding","volume":"63","author":"Liu","year":"2009","journal-title":"Acta Med. Okayama"},{"issue":"28","key":"10.1016\/j.ejphar.2025.177989_bib21","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177989_bib22","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1159\/000489375","article-title":"Unfractionated heparin alleviates human lung endothelial barrier dysfunction induced by high mobility group box 1 through regulation of P38-GSK3\u03b2-Snail signaling pathway","volume":"46","author":"Luan","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2025.177989_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.757415","article-title":"Peripheral neuropathy during concomitant administration of proteasome inhibitors and factor Xa inhibitors: identifying the likelihood of drug-drug interactions","volume":"13","author":"Meng","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"25","key":"10.1016\/j.ejphar.2025.177989_bib24","doi-asserted-by":"crossref","first-page":"16722","DOI":"10.1016\/S0021-9258(18)55361-8","article-title":"30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane","volume":"266","author":"Merenmies","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.ejphar.2025.177989_bib25","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.177989_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tox.2016.07.016","article-title":"Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats","volume":"365","author":"Nishida","year":"2016","journal-title":"Toxicology"},{"issue":"5","key":"10.1016\/j.ejphar.2025.177989_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177989_bib28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177989_bib29","doi-asserted-by":"crossref","first-page":"C97","DOI":"10.1152\/ajpcell.00009.2010","article-title":"Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands","volume":"299","author":"Rao","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177989_bib30","article-title":"Inhibition of homophilic interactions and ligand binding of the receptor for advanced glycation end products by heparin and heparin-related carbohydrate structures","volume":"5","author":"Rouhiainen","year":"2018","journal-title":"Medicines (Basel)"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177989_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1189\/jlb.0306200","article-title":"Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (Amphoterin)","volume":"81","author":"Rouhiainen","year":"2007","journal-title":"J. Leukoc. Biol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177989_bib32","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177989_bib33","first-page":"167","article-title":"Safety of proteasome inhibitors for treatment of multiple myeloma","volume":"16","author":"Schlafer","year":"2017","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177989_bib34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2018.08.040","article-title":"Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: evidence for a neuroimmune crosstalk","volume":"141","author":"Sekiguchi","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177989_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism","volume":"41","author":"Smythe","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177989_bib36","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2025.177989_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2013.11.003","article-title":"Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis","volume":"79","author":"Tanaka","year":"2014","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177989_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12974-019-1581-6","article-title":"Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin\/thrombomodulin system in rodents: negative impact of anticoagulants","volume":"16","author":"Tsubota","year":"2019","journal-title":"J. Neuroinflammation"},{"issue":"10","key":"10.1016\/j.ejphar.2025.177989_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102550","article-title":"Caspase-dependent HMGB1 release from macrophages participates in peripheral neuropathy caused by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice","volume":"10","author":"Tsubota","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177989_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1529-8027.2010.00248.x","article-title":"Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients","volume":"15","author":"Velasco","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177989_bib41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1574892815666200401113805","article-title":"Bortezomib - first therapeutic proteasome inhibitor for cancer therapy: a review of patent literature","volume":"15","author":"Vora","year":"2020","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177989_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/psp4.12267","article-title":"Translational biomedical informatics and pharmacometrics approaches in the drug interactions research","volume":"7","author":"Zhang","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925007435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925007435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:25:25Z","timestamp":1772792725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925007435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":42,"alternative-id":["S0014299925007435"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177989","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant use of low molecular weight heparin mitigates bortezomib-induced peripheral Neuropathy: Analysis of the FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177989"}}